Progress and problems in the application of focused ultrasound for blood-brain barrier disruption

Ultrasonics

Volumn 48, Issue 4, 2008, Pages 279-296

  Vykhodtseva, Natalia ^a   McDannold, Nathan ^a   Hynynen, Kullervo ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Blood brain barrier; Brain; Drug delivery; Ultrasound

Indexed keywords

ACOUSTIC WAVES; BLOOD; BLOOD VESSELS; CHEMOTHERAPY; DRUG DELIVERY; DRUG DOSAGE; HEALTH; NEUROLOGY; PROTEINS; ULTRASONIC TRANSMISSION; ULTRASONICS;

BLOOD BRAIN BARRIER (BBB); BLOOD VESSEL WALLS; BLOOD-BRAIN BARRIER DISRUPTION; CENTRAL NERVOUS SYSTEM (CNS); DELIVERY METHODS; ELSEVIER (CO); FOCUSED ULTRASOUND (FUS); RECOMBINANT PROTEINS; TARGETED DRUG DELIVERY;

STABILIZERS (AGENTS);

ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; MONOCLONAL ANTIBODY;

ANIMAL; BLOOD BRAIN BARRIER; DIFFUSION; DRUG DELIVERY SYSTEM; GENE THERAPY; HUMAN; INSTRUMENTATION; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; METABOLISM; METHODOLOGY; MICROBUBBLE; REVIEW; ULTRASOUND THERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; CONTRAST MEDIA; DIFFUSION; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MICROBUBBLES; ULTRASONIC THERAPY;

EID: 48149101439     PISSN: 0041624X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ultras.2008.04.004     Document Type: Review

References (211)

1. Pardridge W.M. Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev. Drug. Discov. 1 2 (2002) 131-139
2. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2 1 (2005) 3-14
3. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol. Interv. 3 2 (2003) 90-105 51
4. Ajay A., Bemis G.W., and Murcko M.A. Designing libraries with CNS activity. J. Med. Chem. 42 24 (1999) 4942-4951
5. Ghose A.K., Viswanadhan V.N., and Wendoloski J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1 1 (1999) 55-68
6. Pardridge W.M. Advances in cell biology of blood-brain barrier transport. Semin. Cell. Biol. 2 6 (1991) 419-426
7. Pardridge W.M. Drug and gene delivery to the brain: the vascular route. Neuron 36 4 (2002) 555-558
8. Lo E.H., Singhal A.B., Torchilin V.P., and Abbott N.J. Drug delivery to damaged brain. Brain Res. Brain Res. Rev. 38 1-2 (2001) 140-148
9. Doolittle N.D., Anderson C.P., Bleyer W.A., Cairncross J.G., Cloughesy T., Eck S.L., Guastadisegni P., Hall W.A., Muldoon L.L., Patel S.J., Peereboom D., Siegal T., and Neuwelt E.A. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro-Oncology 3 1 (2001) 46-54
10. Pardridge W.M. Brain drug targeting and gene technologies. Jpn. J. Pharmacol. 87 2 (2001) 97-103
11. Krewson C.E., Klarman M.L., and Saltzman W.M. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res. 680 1-2 (1995) 196-206
12. Krewson C.E., Dause R., Mak M., and Saltzman W.M. Stabilization of nerve growth factor in controlled release polymers and in tissue. J. Biomater. Sci. Polym. Ed. 8 2 (1996) 103-117
13. Guerin C., Olivi A., Weingart J.D., Lawson H.C., and Brem H. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest. New Drugs 22 1 (2004) 27-37
14. Yan Q., Matheson C., Sun J., Radeke M.J., Feinstein S.C., and Miller J.A. Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression. Exp. Neurol. 127 1 (1994) 23-36
15. Morrison P.F., Laske D.W., Bobo H., Oldfield E.H., and Dedrick R.L. High-flow microinfusion: tissue penetration and pharmacodynamics. Am. J. Physiol. 266 1 Pt 2 (1994) R292-R305
16. Ai Y., Markesbery W., Zhang Z., Grondin R., Elseberry D., Gerhardt G.A., and Gash D.M. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J. Comp. Neurol. 461 2 (2003) 250-261
17. Reszka R.C., Jacobs A., and Voges J. Liposome-mediated suicide gene therapy in humans. Methods Enzymol. 391 (2005) 200-208
18. Voges J., Reszka R., Gossmann A., Dittmar C., Richter R., Garlip G., Kracht L., Coenen H.H., Sturm V., Wienhard K., Heiss W.D., and Jacobs A.H. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. 54 4 (2003) 479-487
19. Grondin R., Zhang Z., Ai Y., Gash D.M., and Gerhardt G.A. Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog. Drug Res. 61 (2003) 101-123
20. Ferguson S., and Lesniak M.S. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr. Drug Deliv. 4 2 (2007) 169-180
21. Fung L.K., Shin M., Tyler B., Brem H., and Saltzman W.M. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm. Res. 13 5 (1996) 671-682
22. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., Gerhardt G.A., and Gash D.M. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp. Neurol. 202 2 (2006) 497-505
23. Manome Y., Kobayashi T., Mori M., Suzuki R., Funamizu N., Akiyama N., Inoue S., Tabata Y., and Watanabe M. Local delivery of doxorubicin for malignant glioma by a biodegradable PLGA polymer sheet. Anticancer Res. 26 5A (2006) 3317-3326
24. Yamanaka R., and Itoh K. Peptide-based immunotherapeutic approaches to glioma: a review. Expert Opin. Biol. Ther. 7 5 (2007) 645-649
25. Aebischer P., and Ridet J. Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci. 24 9 (2001) 533-540
26. Neuwelt E.A., Barnett P.A., McCormick C.I., Frenkel E.P., and Minna J.D. Osmotic blood-brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery 17 3 (1985) 419-423
27. Doolittle N.D., Miner M.E., Hall W.A., Siegal T., Jerome E., Osztie E., McAllister L.D., Bubalo J.S., Kraemer D.F., Fortin D., Nixon R., Muldoon L.L., and Neuwelt E.A. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88 3 (2000) 637-647
28. Hall W.A., Doolittle N.D., Daman M., Bruns P.K., Muldoon L., Fortin D., and Neuwelt E.A. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. J. Neurooncol. 77 3 (2006) 279-284
29. Kroll R.A., and Neuwelt E.A. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42 5 (1998) 1083-1099
30. Matsukado K., Sugita M., and Black K.L. Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas. Brain Res. 792 1 (1998) 10-15
31. Broadwell R.D., Salcman M., and Kaplan R.S. Morphologic effect of dimethyl sulfoxide on the blood-brain barrier. Science 217 4555 (1982) 164-166
32. Saija A., Princi P., Trombetta D., Lanza M., and De Pasquale A. Changes in the permeability of the blood-brain barrier following sodium dodecyl sulphate administration in the rat. Exp. Brain Res. 115 3 (1997) 546-551
33. Gennuso R., Spigelman M.K., Chinol M., Zappulla R.A., Nieves J., Vallabhajosula S., Alberto P.P., Goldsmith S.J., and Holland J.F. Effect of blood-brain barrier and blood-tumor barrier modification on central nervous system liposomal uptake. Cancer Invest. 11 2 (1993) 118-128
34. Cornford E.M., Young D., Paxton J.W., Finlay G.J., Wilson W.R., and Pardridge W.M. Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res. 52 1 (1992) 138-143
35. Rabchevsky A.G., Degos J.D., and Dreyfus P.A. Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res. 832 1-2 (1999) 84-96
36. Bolton S.J., Anthony D.C., and Perry V.H. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 86 4 (1998) 1245-1257
37. Anthony D., Dempster R., Fearn S., Clements J., Wells G., Perry V.H., and Walker K. CXC chemokines generate age-related increases in neutrophil-mediated brain inflammation and blood-brain barrier breakdown. Curr. Biol. 8 16 (1998) 923-926
38. Oztas B., and Kucuk M. Reversible blood-brain barrier dysfunction after intracarotid hyperthermic saline infusion. Int. J. Hyperthermia 14 4 (1998) 395-401
39. Oztas B., and Kucuk M. Intracarotid hypothermic saline infusion: a new method for reversible blood-brain barrier disruption in anesthetized rats. Neurosci. Lett. 190 3 (1995) 203-206
40. Nadal A., Fuentes E., Pastor J., and McNaughton P.A. Plasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes. Proc. Natl. Acad. Sci. U.S.A. 92 5 (1995) 1426-1430
41. Dietz G.P., and Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 27 2 (2004) 85-131
42. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47 1 (2001) 65-81
43. Pardridge W.M. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin. Biol. Ther. 4 7 (2004) 1103-1113
44. Pardridge W.M. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx 2 1 (2005) 129-138
45. Koziara J.M., Lockman P.R., Allen D.D., and Mumper R.J. The blood-brain barrier and brain drug delivery. J. Nanosci. Nanotechnol. 6 9-10 (2006) 2712-2735
46. Huwyler J., Wu D., and Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U.S.A. 93 24 (1996) 14164-14169
47. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16 10 (1999) 1564-1569
48. Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des. 5 6 (1999) 443-451
49. Pardridge W.M., Kang Y.S., and Buciak J.L. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharm. Res. 11 5 (1994) 738-746
50. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 5433 (1999) 1569-1572
51. Pardridge W.M. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm. Sci. Technol. Today 2 2 (1999) 49-59
52. Bickel U., Yoshikawa T., and Pardridge W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46 1-3 (2001) 247-279
53. Pardridge W.M. Neurotrophins, neuroprotection and the blood-brain barrier. Curr. Opin. Invest. Drugs 3 12 (2002) 1753-1757
54. Schlachetzki F., Zhang Y., Boado R.J., and Pardridge W.M. Gene therapy of the brain: the trans-vascular approach. Neurology 62 8 (2004) 1275-1281
55. Pardridge W.M. Molecular Trojan horses for blood-brain barrier drug delivery. Curr. Opin. Pharmacol. 6 5 (2006) 494-500
56. Wu D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx 2 1 (2005) 120-128
57. Penas-Prado M., and Gilbert M.R. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev. Anticancer Ther. 7 5 (2007) 641-661
58. Hynynen K. Biophysics and technology of ultrasound hyperthermia. In: Gautherie M. (Ed). Methods of External Hyperthermic Heating (1990), Springer-Verlag, New York 61-115
59. Diederich C.J., and Hynynen K. Ultrasound technology for hyperthermia. Ultrasound Med. Biol. 25 (1999) 871-887
60. Hunt J.W. Principles of ultrasound used for generating localized hyperthermia. In: Field S.B., and Hand J.W. (Eds). Principle Aspects of Clinical Hyperthermia (1990), Taylor and Francis, London 371-422
61. Lele P.P. Local hyperthermia by ultrasound. In: Nussbaum G.H. (Ed). Physical Aspects of Hyperthermia (1982), American Institute of Physics, New York 393-440
62. K. Hynynen, G. Clement, N. McDannold, R. King, P.J. White, F. Jolesz, S. Vitek, E. Zadicario, Pre-clinical testing of a phased array ultrasound system for MRI-guided noninvasive surgery of the brain, in: Proceedings of the Eleventh Meeting of the International Society for Magnetic Resonance in Medicine, Toronto, ON, 2003, p. 77.
63. Chan A.H., Fujimoto V.Y., Moore D.E., Martin R.W., and Vaezy S. An image-guided high intensity focused ultrasound device for uterine fibroids treatment. Med. Phys. 29 11 (2002) 2611-2620
64. Chapelon J.Y., Ribault M., Vernier F., Souchon R., and Gelet A. Treatment of localised prostate cancer with transrectal high intensity focused ultrasound. Eur. J. Ultrasound 9 1 (1999) 31-38
65. Chen W., Wang Z., Wu F., Zhu H., Zou J., Bai J., Li K., and Xie F. High intensity focused ultrasound in the treatment of primary malignant bone tumor. Zhonghua Zhong Liu Za Zhi 24 6 (2002) 612-615
66. Gelet A., Chapelon J.Y., Poissonnier L., Bouvier R., Rouviere O., Curiel L., Janier M., and Vallancien G. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63 4 (2004) 625-629
67. Wu F., Wang Z.B., Cao Y.D., Chen W.Z., Bai J., Zou J.Z., and Zhu H. A randomised clinical trial of high-intensity focused ultrasound ablation for the treatment of patients with localised breast cancer. Br. J. Cancer 89 12 (2003) 2227-2233
68. Gianfelice D., Khiat A., Amara M., Belblidia A., and Boulanger Y. MR imaging-guided focused ultrasound surgery of breast cancer: correlation of dynamic contrast-enhanced MRI with histopathologic findings. Breast Cancer Res. Treat. 82 2 (2003) 93-101
69. Kohrmann K.U., Michel M.S., Gaa J., Marlinghaus E., and Alken P. High intensity focused ultrasound as noninvasive therapy for multilocal renal cell carcinoma: case study and review of the literature. J. Urol. 167 6 (2002) 2397-2403
70. Tempany C.M., Stewart E.A., McDannold N., Quade B.J., Jolesz F.A., and Hynynen K. MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology 226 3 (2003) 897-905
71. ter Haar G.R. High intensity focused ultrasound for the treatment of tumors. Echocardiography 18 4 (2001) 317-322
72. Wu F., Wang Z.B., Chen W.Z., Zhu H., Bai J., Zou J.Z., Li K.Q., Jin C.B., Xie F.L., and Su H.B. Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma. Ann. Surg. Oncol. 11 12 (2004) 1061-1069
73. Vaezy S., Noble M.L., Keshavarzi A., Paun M., Prokop A.F., Cornejo C., Sharar S., Chi E.Y., Crum L.A., and Martin R.W. Liver hemostasis with high-intensity ultrasound: repair and healing. J. Ultrasound Med. 23 2 (2004) 217-225
74. Hwang J.H., Vaezy S., Martin R.W., Cho M.Y., Noble M.L., Crum L.A., and Kimmey M.B. High-intensity focused US: a potential new treatment for GI bleeding. Gastrointest. Endosc. 58 1 (2003) 111-115
75. Noble M.L., Vaezy S., Keshavarzi A., Paun M., Prokop A.F., Chi E.Y., Cornejo C., Sharar S.R., Jurkovich G.J., Martin R.W., and Crum L.A. Spleen hemostasis using high-intensity ultrasound: survival and healing. J. Trauma 53 6 (2002) 1115-1120
76. Vaezy S., Martin R., and Crum L. High intensity focused ultrasound: a method of hemostasis. Echocardiography 18 4 (2001) 309-315
77. Hynynen K., Colucci V., Chung A., and Jolesz F. Noninvasive arterial occlusion using MRI-guided focused ultrasound. Ultrasound Med. Biol. 22 8 (1996) 1071-1077
78. Rivens I.H., Rowland I.J., Denbow M., Fisk N.M., ter Haar G.R., and Leach M.O. Vascular occlusion using focused ultrasound surgery for use in fetal medicine. Eur. J. Ultrasound 9 1 (1999) 89-97
79. K. Hynynen, J. Sun, G. Clement, J. Thierman, D. Daum, N. I. Vykhodtseva, N.J. McDannold, Phased array development for noninvasive focused ultrasound therapy of brain and liver, in: Proceedings of the First Joint BMES/EMBS Conference, 1999, p. 1270.
80. Hynynen K., and Jolesz F.A. Demonstration of potential noninvasive ultrasound brain therapy through an intact skull. Ultrasound Med. Biol. 24 2 (1998) 275-283
81. Sun J., and Hynynen K. The potential of transskull ultrasound therapy and surgery using the maximum available skull surface area. J. Acoust. Soc. Am. 105 4 (1999) 2519-2527
82. Clement G.T., and Hynynen K. A non-invasive method for focusing ultrasound through the human skull. Phys. Med. Biol. 47 8 (2002) 1219-1236
83. Sun J., and Hynynen K. Focusing of therapeutic ultrasound through a human skull: a numerical study. J. Acoust. Soc. Am. 104 3 Pt 1 (1998) 1705-1715
84. Pernot M., Aubry J.F., Tanter M., Thomas J.L., and Fink M. High power transcranial beam steering for ultrasonic brain therapy. Phys. Med. Biol. 48 16 (2003) 2577-2589
85. Aubry J.F., Tanter M., Pernot M., Thomas J.L., and Fink M. Experimental demonstration of noninvasive transskull adaptive focusing based on prior computed tomography scans. J. Acoust. Soc. Am. 113 1 (2003) 84-93
86. Yin X., and Hynynen K. A numerical study of transcranial focused ultrasound beam propagation at low frequency. Phys. Med. Biol. 50 8 (2005) 1821-1836
87. Hynynen K., Clement G., McDannold N., and Vykhodtseva N. The feasibility of noninvasive image-guided treatments of brain disodereds by focused ultrasound. J. Acoust. Soc. Am. 115 5 (2004) 2446
88. Hynynen K., Clement G.T., McDannold N., Vykhodtseva N., King R., White P.J., Vitek S., and Jolesz F.A. 500-Element ultrasound phased array system for noninvasive focal surgery of the brain: a preliminary rabbit study with ex vivo human skulls. Magn. Reson. Med. 52 1 (2004) 100-107
89. Barnard J.W., Fry W.J., Fry F.J., and Krumins R.F. Effects of high intensity ultrasound on the central nervous system of the cat. J. Comp. Neurol. 103 3 (1955) 459-484
90. Bakay L., Hueter T.F., Ballantine Jr. H.T., and Sosa D. Ultrasonically produced changes in the blood-brain barrier. Arch. Neurol. Psychat. (1956) 457-467
91. Ballantine Jr. H.T., Bell E., and Manlapaz J. Progress and problems in the neurological applications of focused ultrasound. J. Neurosurg. 17 (1960) 858-876
92. Astrom K.E., Bell Ballantine Jr. H.T., and Heidensleben E. An experimental neuropathological study of the effects of high-frequency focused ultrasound on the brain of the cat. J. Neuropathol. Exp. Neurol. 20 (1961) 484-520
93. Basauri L., and Lele P.P. A simple method for production of trackless focal lesions with focused ultrasound: statistical evaluation of the effects of irradiation on the central nervous system of the cat. J. Physiol. 160 3 (1962) 513-534
94. Warwick R., and Pond J. Trackless lesions in nervous tissues produced by high intensity focused ultrasound (high-frequency mechanical waves). J. Anat. 102 3 (1968) 387-405
95. Vykhodtseva N.I., Gavrilov L.R., Mering T.A., and Iamshchikova N.G. [Use of focused ultrasound for local destruction of different brain structures] Primenenie fokusirovannogo ul'trazvuka dlia lokal'nykh razrushenii razlichnykh struktur golovnogo mozga. Zh. Nevropatol. Psikhiatr. 76 12 (1976) 1810-1816
96. N. Vykhodtseva, Effects of high intensity pulsed ultrasound on brain tissues, in: Proceedings of the 5th International Symposium on Ultrasound in Biol. Med., Puschino, Russia, 1981, pp. 95-97.
97. Hynynen K., McDannold N., Vykhodtseva N., and Jolesz F.A. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220 3 (2001) 640-646
98. Hynynen K., McDannold N., Martin H., Jolesz F.A., and Vykhodtseva N. The threshold for brain damage in rabbits induced by bursts of ultrasound in the presence of an ultrasound contrast agent (Optison). Ultrasound Med. Biol. 29 3 (2003) 473-481
99. Hynynen K., McDannold N., Vykhodtseva N., and Jolesz F.A. Non-invasive opening of BBB by focused ultrasound. Acta Neurochir. Suppl. 86 (2003) 555-558
100. Hynynen K., McDannold N., Sheikov N.A., Jolesz F.A., and Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24 1 (2005) 12-20
101. Hynynen K., McDannold N., Vykhodtseva N., Raymond S., Weissleder R., Jolesz F.A., and Sheikov N. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J. Neurosurg. 105 3 (2006) 445-454
102. Patrick J.T., Nolting M.N., Goss S.A., Dines K.A., Clendenon J.L., Rea M.A., and Heimburger R.F. Ultrasound and the blood-brain barrier. Adv. Exp. Med. Biol. 267 (1990) 369-381
103. Vykhodtseva N.I., Hynynen K., and Damianou C. Histologic effects of high intensity pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo. Ultrasound Med. Biol. 21 7 (1995) 969-979
104. Mesiwala A.H., Farrell L., Wenzel H.J., Silbergeld D.L., Crum L.A., Winn H.R., and Mourad P.D. High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound Med. Biol. 28 3 (2002) 389-400
105. Vykhodtseva N.I., Sorrentino V., Jolesz F.A., Bronson R.T., and Hynynen K. MRI detection of the thermal effects of focused ultrasound on the brain. Ultrasound Med. Biol. 26 5 (2000) 871-880
106. N. Vykhodtseva, N. McDannold, S. Agabian, K. Hynynen, Histology findings after ultrasound exposure of the brain with ultrasound contrast agent - role of ischemia and apoptosis, in: Proceedings of the Third International Symposium on Therapeutic Ultrasound, 22-25 June, Lyon, France, 2003, pp. 80-85.
107. McDannold N., Vykhodtseva N., Raymond S., Jolesz F.A., and Hynynen K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med. Biol. 31 11 (2005) 1527-1537
108. McDannold N., Vykhodtseva N., and Hynynen K. Blood-brain barrier disruption induced by focused ultrasound and circulating preformed microbubbles appears to be characterized by the mechanical index. Ultrasound Med. Biol. 34 (2008) 834-840
109. McDannold N., Vykhodtseva N., and Hynynen K. Targeted disruption of the blood-brain barrier with focused ultrasound: association with cavitation activity. Phys. Med. Biol. 51 4 (2006) 793-807
110. McDannold N., Vykhodtseva N., and Hynynen K. Use of ultrasound pulses combined with definity for targeted blood-brain barrier disruption: a feasibility study. Ultrasound Med. Biol. 33 4 (2007) 584-590
111. Treat L.H., McDannold N., Vykhodtseva N., Zhang Y., Tam K., and Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int. J. Cancer 121 4 (2007) 901-907
112. N. McDannold, N. Vykhodtseva, K. Hynynen, Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption, Ultrasound Med. Biol. (2008), in press.
113. K. Hynynen, N. McDannold, L. Josphson, N. Vykhodtseva, R. Weisleder, F.A. Jolesz, Noninvasive MRI-guided focal opening of the blood brain barrier: demonstration of large particle penetration, in: Proceedings of the Tenth Meeting of the International Society for Magnetic Resonance in Medicine, Honolulu, HI, 2002, p. 332.
114. Kinoshita M., McDannold N., Jolesz F.A., and Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc. Natl. Acad. Sci. U.S.A. 103 31 (2006) 11719-11723
115. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 5517 (1975) 495-497
116. Cersosimo R.J. Monoclonal antibodies in the treatment of cancer, Part 1. Am. J. Health Syst. Pharm. 60 15 (2003) 1531-1548
117. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5 5 (2004) 292-302
118. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. J. Immunol. 174 5 (2005) 2453-2455 (1975)
119. Gerber D.E., and Laterra J. Emerging monoclonal antibody therapies for malignant gliomas. Expert Opin. Invest. Drugs 16 4 (2007) 477-494
120. Segota E., and Bukowski R.M. The promise of targeted therapy: cancer drugs become more specific. Cleve Clin. J. Med. 71 7 (2004) 551-560
121. Ross J.S., Schenkein D.P., Pietrusko R., Rolfe M., Linette G.P., Stec J., Stagliano N.E., Ginsburg G.S., Symmans W.F., Pusztai L., and Hortobagyi G.N. Targeted therapies for cancer 2004. Am. J. Clin. Pathol. 122 4 (2004) 598-609
122. Sharkey R.M., and Goldenberg D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46 Suppl. 1 (2005) 115S-127S
123. Zalutsky M.R. Current status of therapy of solid tumors: brain tumor therapy. J. Nucl. Med. 46 Suppl. 1 (2005) 151S-156S
124. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 6815 (2000) 979-982
125. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., Spooner E.T., Jiang L., Anwyl R., Selkoe D.J., and Rowan M.J. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11 5 (2005) 556-561
126. Kemper E.M., Boogerd W., Thuis I., Beijnen J.H., and van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?. Cancer Treat. Rev. 30 5 (2004) 415-423
127. Dietlein M., Pels H., Schulz H., Staak O., Borchmann P., Schomacker K., Fischer T., Eschner W., Pogge V.S., Schicha H., Engert A., and Schnell R. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur. J. Haematol. 74 4 (2005) 348-352
128. Neuwelt E.A., Specht H.D., Barnett P.A., Dahlborg S.A., Miley A., Larson S.M., Brown P., Eckerman K.F., Hellstrom K.E., and Hellstrom I. Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 20 6 (1987) 885-895
129. Reardon D.A., Akabani G., Coleman R.E., Friedman A.H., Friedman H.S., Herndon J.E., Cokgor I., McLendon R.E., Pegram C.N., Provenzale J.M., Quinn J.A., Rich J.N., Regalado L.V., Sampson J.H., Shafman T.D., Wikstrand C.J., Wong T.Z., Zhao X.G., Zalutsky M.R., and Bigner D.D. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20 5 (2002) 1389-1397
130. Haluska M., and Anthony M.L. Osmotic blood-brain barrier modification for the treatment of malignant brain tumors. Clin. J. Oncol. Nurs. 8 3 (2004) 263-267
131. Kinoshita M., McDannold N., Jolesz F.A., and Hynynen K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem. Biophys. Res. Commun. 340 4 (2006) 1085-1090
132. Benz C.C., O'Hagan R.C., Richter B., Scott G.K., Chang C.H., Xiong X., Chew K., Ljung B.M., Edgerton S., Thor A., and Hassell J.A. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 15 13 (1997) 1513-1525
133. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics, 2006. CA Cancer J. Clin. 56 2 (2006) 106-130
134. Bell R. What can we learn from Herceptin trials in metastatic breast cancer?. Oncology 63 Suppl. 1 (2002) 39-46
135. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., and Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 11 (2001) 783-792
136. Fenner M.H., and Possinger K. Chemotherapy for breast cancer brain metastases. Onkologie 25 5 (2002) 474-479
137. Bendell J.C., Domchek S.M., Burstein H.J., Harris L., Younger J., Kuter I., Bunnell C., Rue M., Gelman R., and Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97 12 (2003) 2972-2977
138. Burstein H.J., Lieberman G., Slamon D.J., Winer E.P., and Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann. Oncol. 16 11 (2005) 1772-1777
139. Lower E.E., Drosick D.R., Blau R., Brennan L., Danneman W., and Hawley D.K. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin. Breast Cancer 4 2 (2003) 114-119
140. Takemura G., and Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 49 5 (2007) 330-352
141. Scartozzi M., Galizia E., Verdecchia L., Berardi R., Antognoli S., Chiorrini S., and Cascinu S. Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin. Pharmacother. 8 6 (2007) 797-808
142. van Ditzhuijsen C.I., van de W.R., and Haak H.R. Adrenocortical carcinoma. Neth. J. Med. 65 2 (2007) 55-60
143. von Minckwitz G. Docetaxel/anthracycline combinations for breast cancer treatment. Expert Opin. Pharmacother. 8 4 (2007) 485-495
144. Bristol I.J., and Buchholz T.A. Inflammatory breast cancer: current concepts in local management. Breast Dis. 22 (2005) 75-83
145. Ulrich-Pur H., Kornek G.V., Haider K., Kwasny W., Payrits T., Dworan N., Vormittag L., Depisch D., Lang F., and Scheithauer W. Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer. Acta Oncol. 46 2 (2007) 208-213
146. Thigpen J.T., Aghajanian C.A., Alberts D.S., Campos S.M., Gordon A.N., Markman M., McMeekin D.S., Monk B.J., and Rose P.G. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol. Oncol. 96 1 (2005) 10-18
147. Recchia F., Saggio G., Amiconi G., Di Blasio A., Cesta A., Candeloro G., Carta G., Necozione S., Mantovani G., and Rea S. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecol. Oncol. 106 (2007) 164-169
148. Pignata S., Scambia G., Pisano C., Breda E., Di Maio M., Greggi S., Ferrandina G., Lorusso D., Zagonel V., Febbraro A., Riva N., De R.V., Gallo C., and Perrone F. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br. J. Cancer 96 (2007) 1639-1643
149. Wang X., Pang L., and Feng J. A phase II study of etoposide, doxorubicin, and carboplatin in the treatment of advanced gastric cancer. Am. J. Clin. Oncol. 25 1 (2002) 71-75
150. Ardizzoni A., Tjan-Heijnen V.C., Postmus P.E., Buchholz E., Biesma B., Karnicka-Mlodkowska H., Dziadziuszko R., Burghouts J., Van Meerbeeck J.P., Gans S., Legrand C., Debruyne C., Giaccone G., and Manegold C. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923. J. Clin. Oncol. 20 19 (2002) 3947-3955
151. Gilliam L.K., Kohn A.D., Lalani T., Swanson P.E., Vasko V., Patel A., Livingston R.B., and Pickett C.A. Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid 16 8 (2006) 801-810
152. Palmieri C., Treibel T., Large O., and Bower M. AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. QJM 99 12 (2006) 811-826
153. Laskar S., Gupta T., Vimal S., Muckaden M.A., Saikia T.K., Pai S.K., Naresh K.N., and Dinshaw K.A. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. J. Clin. Oncol. 22 1 (2004) 62-68
154. Pulini S., Rupoli S., Goteri G., Pimpinelli N., Alterini R., Tassetti A., Scortechini A.R., Offidani M., Mulattieri S., Stronati A., Brandozzi G., Giacchetti A., Mozzicafreddo G., Ricotti G., Filosa G., Bettacchi A., Simonacci M., Novelli N., and Leoni P. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica 92 5 (2007) 686-689
155. Hawkins D.S., and Arndt C.A. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98 11 (2003) 2447-2456
156. Grobmyer S.R., Maki R.G., Demetri G.D., Mazumdar M., Riedel E., Brennan M.F., and Singer S. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann. Oncol. 15 11 (2004) 1667-1672
157. Leo E., Schlegel P.G., and Lindemann A. Chemotherapeutic induction of long-term remission in metastatic medulloblastoma. J. Neurooncol. 32 2 (1997) 149-154
158. Stan A.C., Casares S., Radu D., Walter G.F., and Brumeanu T.D. Doxorubicin-induced cell death in highly invasive human gliomas. Anticancer Res. 19 2A (1999) 941-950
159. Muldoon L.L., and Neuwelt E.A. BR96-DOX immunoconjugate targeting of chemotherapy in brain tumor models. J. Neurooncol. 65 1 (2003) 49-62
160. Gupta B., and Torchilin V.P. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother. 56 8 (2007) 1215-1223
161. Cummings J., and McArdle C.S. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br. J. Cancer 53 6 (1986) 835-838
162. Tokarska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., and Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J. Mol. Cell Cardiol. 41 3 (2006) 389-405
163. Ferreira A.L., Salvadori D.M., Nascimento M.C., Rocha N.S., Correa C.R., Pereira E.J., Matsubara L.S., Matsubara B.B., and Ladeira M.S. Tomato-oleoresin supplement prevents doxorubicin-induced cardiac myocyte oxidative DNA damage in rats. Mutat. Res. 631 (2007) 26-35
164. Flynn H.G. Physics of acoustic cavitation in liquids. In: Mason W.P. (Ed). Physical Acoustics, Principles and Methods (1964), Academic Press, New York
165. Frizzell L.A. Biologic effects of acoustic cavitation. In: Suslick K.S. (Ed). Ultrasound its Chemical Physical and Biological Effects (1998), VCH, New York 287-303
166. Nyborg W.L. Biological effects of ultrasound: development of safety guidelines. Part II: general review. Ultrasound Med. Biol. 27 3 (2001) 301-333
167. Hsieh D.Y., and Plesset M.S. Theory of rectified diffusion of mass into gas bubbles. J. Acoust. Soc. Am. 33 (1961) 206-211
168. Nyborg W.L. Acoustic streaming. In: Mason W.P. (Ed). Physical Acoustics (1965), Academic Press, New York
169. Miller D.L. A review of the ultrasonic bioeffects of microsonation, gas-body activation, and related cavitation-like phenomena. Ultrasound Med. Biol. 13 8 (1987) 443-470
170. Krizanac-Bengez L., Mayberg M.R., and Janigro D. The cerebral vasculature as a therapeutic target for neurological disorders and the role of shear stress in vascular homeostatis and pathophysiology. Neurol. Res. 26 8 (2004) 846-853
171. Leighton T. The Acoustic Bubble (1994), Academic Press, Sand Diego
172. Hamill O.P. Twenty odd years of stretch-sensitive channels. Pflugers Arch. 453 3 (2006) 333-351
173. Mihran R.T., Barnes F.S., and Wachtel H. Temporally-specific modification of myelinated axon excitability in vitro following a single ultrasound pulse. Ultrasound Med. Biol. 16 3 (1990) 297-309
174. Mihran R.T., Barnes F.S., and Wachtel H. Transient modification of nerve excitability in vitro by single ultrasound pulses. Biomed. Sci. Instrum. 26 (1990) 235-246
175. Apfel R.E. Acoustic cavitation: a possible consequence of biomedical uses of ultrasound. Br. J. Cancer Suppl. 45 5 (1982) 140-146
176. Flynn H.G. Generation of transient cavities in liquids by microsecond pulses of ultrasound. J. Acoust. Soc. Am. 72 (1982) 1926-1932
177. Brujan E.A. The role of cavitation microjets in the therapeutic applications of ultrasound. Ultrasound Med. Biol. 30 3 (2004) 381-387
178. Katz J.I. Jets from collapsing bubbles. Proc. R. Soc. London, Ser. A. 455 (1999) 323-328
179. Riesz P., and Kondo T. Free radical formation induced by ultrasound and its biological implications. Free Radical Biol. Med. 13 3 (1992) 247-270
180. Edmonds P.D., and Sancier K.M. Evidence for free radical production by ultrasonic cavitation in biological media. Ultrasound Med. Biol. 9 6 (1983) 635-639
181. Kondo T., Kodaira T., and Kano E. Free radical formation induced by ultrasound and its effects on strand breaks in DNA of cultured FM3A cells. Free Radical Res. Commun. 19 Suppl. 1 (1993) S193-S200
182. Deng C.X., Sieling F., Pan H., and Cui J. Ultrasound-induced cell membrane porosity. Ultrasound Med. Biol. 30 4 (2004) 519-526
183. Miller M.W., Miller D.L., and Brayman A.A. A review of in vitro bioeffects of inertial ultrasonic cavitation from a mechanistic perspective. Ultrasound Med. Biol. 22 9 (1996) 1131-1154
184. Miller D.L., and Thomas R.M. Ultrasound contrast agents nucleate inertial cavitation in vitro. Ultrasound Med. Biol. 21 8 (1995) 1059-1065
185. van Wamel A., Bouakaz A., Versluis M., and de Jong N. Micromanipulation of endothelial cells: ultrasound-microbubble-cell interaction. Ultrasound Med. Biol. 30 9 (2004) 1255-1258
186. Coakley W.T. Acoustic detection of single cavitation events in a focused field in water at 1 MHz. J. Acoust. Soc. Am. 49 (2006) 792
187. Neppiras E.A. Acoustic cavitation. Phys. Rep. 61 (1980) 160
188. Lele P.P. Effects of ultrasound on solid mammalian tissues and tumors in vivo. In: Repacholi M.H., Grandolfo M., and Rindi A. (Eds). Ultrasound: Medical Applications, Biological Effects and Hazard Potential (1987), Plunum Publishing Corporation, New York 275-306
189. Zhong P., Zhou Y., and Zhu S. Dynamics of bubble oscillation in constrained media and mechanisms of vessel rupture in SWL. Ultrasound Med. Biol. 27 1 (2001) 119-134
190. Sassaroli E., and Hynynen K. Forced linear oscillations of microbubbles in blood capillaries. J. Acoust. Soc. Am. 115 (2004) 3235-3243
191. Sassaroli E., and Hynynen K. Resonance frequency of microbubbles in small blood vessels: a numerical study. Phys. Med. Biol. 50 22 (2005) 5293-5305
192. Cui J., Hamilton M.F., Wilson P.S., and Zabolotskaya E.A. Bubble pulsations between parallel plates. J. Acoust. Soc. Am. 119 4 (2006) 2067-2072
193. Caskey C.F., Kruse D.E., Dayton P., Kitano T.K., and Ferrara K.W. Microbubble oscillations in tubes with diameters of 12, 25, and 195 microns. Appl. Phys. Lett. 88 (2006) 033902
194. Qin S., and Ferrara K.W. Acoustic response of compliable microvessels containing ultrasound contrast agents. Phys. Med. Biol. 27 (2006) 5063-5088
195. Sassaroli E., and Hynynen K. Cavitation thresholds of microbubbles in gel tunnels by focused ultrasound. Ultrasound Med. Biol. 33 10 (2007) 1651-1660
196. Tata D.A., and Anderson B.J. A new method for the investigation of capillary structure. J. Neurosci. Methods 113 2 (2002) 199-206
197. Seylaz J., Charbonne R., Nanri K., Von Euw D., Borredon J., Kacem K., Meric P., and Pinard E. Dynamic in vivo measurement of erythrocyte velocity and flow in capillaries and of microvessel diameter in the rat brain by confocal laser microscopy. J. Cereb. Blood Flow Metab. 19 8 (1999) 863-870
198. Leighton T.G., White P.R., and Marsden M.A. The one-dimensional bubble: an unusual oscillator, with applications to human bioeffects of underwater sound. Eur. J. Phys. 16 (1995) 275-281
199. Leighton T.G., White P.R., and Marsden M.A. Applications of one-dimensional bubbles to lithotripsy, and to diver response to low frequency sound. Acta Acoust. 3 (1995) 517-529
200. Sheikov N., McDannold N., Vykhodtseva N., Jolesz F., and Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med. Biol. 30 7 (2004) 979-989
201. Sheikov N., McDannold N., Jolesz F., Zhang Y.Z., Tam K., and Hynynen K. Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier. Ultrasound Med. Biol. 32 9 (2006) 1399-1409
202. N. Sheikov, N. McDannold, S. Sharma, K. Hynynen, Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium, Ultrasound Med. Biol. (2008), in press.
203. Raymond S.B., Skoch J., Bacskai B.J., and Hynynen K. Modular design for in vivo optical imaging and ultrasound treatment in the murine brain. IEEE Trans. Ultrason Ferroelectr Freq. Control 54 2 (2007) 431-434
204. Raymond S.B., Skoch J., Hynynen K., and Bacskai B.J. Multiphoton imaging of ultrasound/Optison mediated cerebrovascular effects in vivo. J. Cereb. Blood Flow Metab. 27 2 (2007) 393-403
205. Somjen G.G. Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol. Rev. 81 3 (2001) 1065-1096
206. Leao A.A.P. Pial circulation and spreading depression activity in cerebral cortex. J. Neurophysiol. 7 (1944) 391-396
207. Yanamoto H., Xue J.H., Miyamoto S., Nagata I., Nakano Y., Murao K., and Kikuchi H. Spreading depression induces long-lasting brain protection against infarcted lesion development via BDNF gene-dependent mechanism. Brain Res. 1019 1-2 (2004) 178-188
208. Yanamoto H., Miyamoto S., Tohnai N., Nagata I., Xue J.H., Nakano Y., Nakajo Y., and Kikuchi H. Induced spreading depression activates persistent neurogenesis in the subventricular zone, generating cells with markers for divided and early committed neurons in the caudate putamen and cortex. Stroke 36 7 (2005) 1544-1550
209. Gursoy-Ozdemir Y., Qiu J., Matsuoka N., Bolay H., Bermpohl D., Jin H., Wang X., Rosenberg G.A., Lo E.H., and Moskowitz M.A. Cortical spreading depression activates and upregulates MMP-9. J. Clin. Invest. 113 10 (2004) 1447-1455
210. N. Vykhodtseva, V.I. Koroleva, Steady potential changes and spreading depression in rat brains produced by focused ultrasound, in: G. Clement et al. (Ed.), Therapeutic Ultrasound, AIP Conference Proceedings ISTU2005, Boston, MA, 2006, pp. 313-317.
211. N. Vykhodtseva, I.I. Konopatskaya, V.I. Koroleva, Focused ultrasound potential to initiate spreading depression for disruption of blood-brain barrier, in: 2007 IEEE Ultrasonics Symposium New York City, NY, 28-31 October 2007, pp. 428-431.